	US 12,084,653 B2
	Methods for using transcription-dependent directed evolution of AAV capsids
Hiroyuki Nakai, Portland, OR (US); Samuel Huang, Portland, OR (US); and Kei Adachi, Portland, OR (US)
Assigned to Oregon Health & Science University, Portland, OR (US)
Filed by Oregon Health & Science University, Portland, OR (US)
Filed on Jan. 27, 2023, as Appl. No. 18/160,796.
Application 18/160,796 is a continuation of application No. 17/822,111, filed on Aug. 24, 2022.
Application 17/822,111 is a continuation of application No. 17/337,341, filed on Jun. 2, 2021, granted, now 11,459,558, issued on Oct. 4, 2022.
Application 17/337,341 is a continuation of application No. PCT/US2020/016273, filed on Jan. 31, 2020.
Claims priority of provisional application 62/799,603, filed on Jan. 31, 2019.
Prior Publication US 2023/0287404 A1, Sep. 14, 2023
Int. Cl. C12N 15/11 (2006.01); C12N 7/00 (2006.01); C12N 15/10 (2006.01); C12N 15/86 (2006.01)

CPC C12N 15/11 (2013.01) [C12N 7/00 (2013.01); C12N 15/1082 (2013.01); C12N 15/86 (2013.01); C12N 2310/11 (2013.01); C12N 2320/33 (2013.01); C12N 2750/14122 (2013.01); C12N 2750/14123 (2013.01); C12N 2750/14142 (2013.01); C12N 2750/14145 (2013.01); C12N 2830/008 (2013.01)]

12 Claims

1. An adeno-associated virus serotype 9 (AAV9) capsid protein comprising an amino acid insertion within loop 8, wherein the amino acid insertion comprises SEQ ID NO: 164, and wherein the AAV9 capsid protein without the amino acid insertion comprises 90% sequence identity to SEQ ID NO: 221.